GSTM1 and cancer: Under this new ordering policy, the pharmacist was required to do the following: (1) verify that the first ESA dose would be administered no sooner than day 6 of hospitalization, (2) verify that the patient had no contraindications to the ESA therapy, such as uncontrolled blood pressure (>185/110 mm Hg), Hb > 12 g/dL, or Hb ≥ 10 g/dL for patients with cancer, active bleeding, or curative cancer, (3) contact the prescriber if contraindications exist, and (4) contact the prescriber to obtain an order for an iron supplement if the patient was not receiving one.